AI Engines For more Details: Perplexity Kagi Labs You
ADHD Treatment: Methylphenidate is primarily prescribed for the management of ADHD in both children and adults. It helps improve attention span, concentration, impulse control, and overall behavior in individuals with ADHD.
Narcolepsy Treatment: Methylphenidate may also be used off-label in the treatment of narcolepsy, a chronic sleep disorder characterized by excessive daytime sleepiness and sudden episodes of sleep.
Improved Focus and Alertness: In individuals with ADHD or narcolepsy, methylphenidate works by increasing the levels of neurotransmitters like dopamine and norepinephrine in the brain. This helps enhance cognitive function, focus, and alertness.
Behavioral Management: Methylphenidate can help reduce hyperactivity and impulsivity in individuals with ADHD, allowing them to better regulate their behavior and engage more effectively in daily activities, including school, work, and social interactions.
Dose-Dependent Effects: The effects of methylphenidate can vary depending on the dosage and formulation used. Immediate-release formulations may have a shorter duration of action but provide more rapid symptom relief, while extended-release formulations offer more sustained symptom control throughout the day.
Side Effects: Common side effects of methylphenidate may include insomnia, decreased appetite, weight loss, headache, stomach upset, irritability, and increased heart rate. In some cases, it may also cause more serious side effects like increased blood pressure, mood changes, or psychiatric symptoms.
Risk of Abuse and Dependence: Methylphenidate has the potential for abuse and dependence, particularly among individuals without ADHD who use it for non-medical purposes to improve focus or enhance cognitive performance.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Allergic Rhinitis (Hay Fever) | 0.9 | 0.3 | 2 |
| Allergies | 1.1 | 0.4 | 1.75 |
| Allergy to milk products | 0.7 | 0.9 | -0.29 |
| Alzheimer's disease | 1.2 | 1.1 | 0.09 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.4 | 1.25 |
| Ankylosing spondylitis | 1.2 | 0.3 | 3 |
| Anorexia Nervosa | 0.5 | -0.5 | |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
| Asthma | 0.8 | 0.4 | 1 |
| Atherosclerosis | 0.8 | 0 | 0 |
| Atrial fibrillation | 0.5 | 0.9 | -0.8 |
| Autism | 1.3 | 1.6 | -0.23 |
| Autoimmune Disease | 0.6 | 0.6 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.3 | 0.3 | |
| Bipolar Disorder | 0.9 | 0.9 | |
| Brain Trauma | 0.3 | -0.3 | |
| Breast Cancer | 0.3 | 0.3 | |
| Cancer (General) | 0.6 | -0.6 | |
| Carcinoma | 0.9 | 0.3 | 2 |
| Celiac Disease | 0.9 | 0.3 | 2 |
| Cerebral Palsy | 0.3 | 0.3 | 0 |
| Chronic Fatigue Syndrome | 0.6 | 0.4 | 0.5 |
| Chronic Kidney Disease | 0.9 | 0 | 0 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.3 | |
| Chronic Urticaria (Hives) | 0.9 | 0.3 | 2 |
| Coagulation / Micro clot triggering bacteria | 0.9 | 0.9 | |
| Cognitive Function | 0.3 | 0.3 | |
| Colorectal Cancer | 2.4 | 0.9 | 1.67 |
| Constipation | 1 | 1 | |
| Coronary artery disease | 0.9 | 0.5 | 0.8 |
| COVID-19 | 1.4 | 0.6 | 1.33 |
| Crohn's Disease | 1.5 | 0.6 | 1.5 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 0.9 | 0.3 | 2 |
| d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
| deep vein thrombosis | 1.1 | 0.3 | 2.67 |
| Depression | 2.7 | 2.2 | 0.23 |
| Eczema | 0.6 | 0.2 | 2 |
| Endometriosis | 1.2 | 0.3 | 3 |
| Epilepsy | 1.4 | 0.4 | 2.5 |
| erectile dysfunction | 0.9 | 0.9 | |
| Fibromyalgia | 0.3 | -0.3 | |
| Functional constipation / chronic idiopathic constipation | 1.5 | 0.5 | 2 |
| gallstone disease (gsd) | 1.1 | 0 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.3 | |
| Generalized anxiety disorder | 1.2 | 0.3 | 3 |
| Gout | 0.3 | 0 | 0 |
| Graves' disease | 0.3 | 0.3 | 0 |
| Gulf War Syndrome | 0.3 | -0.3 | |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.5 | 0.3 | 0.67 |
| Heart Failure | 1.2 | 0 | 0 |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| High Histamine/low DAO | 0.3 | 0.3 | |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.1 | 2 |
| hyperglycemia | 1.5 | 0.4 | 2.75 |
| Hyperlipidemia (High Blood Fats) | 0 | 0 | |
| hypertension (High Blood Pressure | 1 | 0.5 | 1 |
| Hypothyroidism | 0 | 0 | |
| Hypoxia | 1.2 | 1.2 | |
| IgA nephropathy (IgAN) | 0.3 | 0.3 | |
| Inflammatory Bowel Disease | 1.5 | 0.9 | 0.67 |
| Insomnia | 0.3 | 0.4 | -0.33 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 1.5 | 0.6 | 1.5 |
| ischemic stroke | 0.6 | 0.9 | -0.5 |
| Liver Cirrhosis | 1.4 | 1.3 | 0.08 |
| Long COVID | 1.1 | 0.3 | 2.67 |
| Lung Cancer | 0.6 | 0.1 | 5 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.6 | 0.6 | |
| ME/CFS with IBS | 0.3 | -0.3 | |
| ME/CFS without IBS | 0.3 | -0.3 | |
| Menopause | 0 | 0 | |
| Metabolic Syndrome | 1.4 | 0.7 | 1 |
| Mood Disorders | 2.4 | 1.6 | 0.5 |
| multiple chemical sensitivity [MCS] | 0 | 0 | |
| Multiple Sclerosis | 0.9 | 0.5 | 0.8 |
| Multiple system atrophy (MSA) | 0.1 | 0.1 | |
| myasthenia gravis | 0.6 | 0.6 | |
| neuropathic pain | 0.3 | -0.3 | |
| Neuropathy (all types) | 0 | 0.6 | 0 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 0.4 | 2 |
| NonCeliac Gluten Sensitivity | 0.4 | 0.3 | 0.33 |
| Obesity | 1.9 | 1.8 | 0.06 |
| obsessive-compulsive disorder | 1.5 | 0.4 | 2.75 |
| Osteoarthritis | 0.9 | 0.3 | 2 |
| Osteoporosis | 0.9 | 0.4 | 1.25 |
| Parkinson's Disease | 2.1 | 1.1 | 0.91 |
| Polycystic ovary syndrome | 1.2 | 0.3 | 3 |
| Primary sclerosing cholangitis | 0.3 | 0.3 | |
| Psoriasis | 0.5 | 0.4 | 0.25 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.9 | 0.5 | 0.8 |
| Schizophrenia | 0.4 | 0.3 | 0.33 |
| scoliosis | 0.3 | 0.3 | |
| Sjögren syndrome | 0.6 | 0.3 | 1 |
| Sleep Apnea | 0.3 | -0.3 | |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 0.6 | 0.4 | 0.5 |
| Systemic Lupus Erythematosus | 1.1 | 1.1 | |
| Tic Disorder | 0.1 | 0.1 | |
| Tourette syndrome | 0 | 0.3 | 0 |
| Type 1 Diabetes | 1.3 | 0.4 | 2.25 |
| Type 2 Diabetes | 1.8 | 1 | 0.8 |
| Ulcerative colitis | 1.5 | 0.7 | 1.14 |
| Unhealthy Ageing | 0.6 | 0 | 0 |
| Vitiligo | 0.5 | 0 | 0 |
